Detalhe da pesquisa
1.
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncol
; 25(4): 518-528, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547895
2.
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.
J Natl Compr Canc Netw
; 21(12): 1234-1242.e17, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081120
3.
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Lancet Oncol
; 17(12): 1709-1719, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27743922
4.
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).
Br J Cancer
; 115(3): 281-9, 2016 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27404456
5.
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Acta Oncol
; 55(9-10): 1168-1174, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27333436
6.
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
JAMA
; 315(17): 1844-53, 2016 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27139057
7.
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 16(15): 1493-1505, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26474518
8.
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
BMC Cancer
; 15: 653, 2015 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26445094
9.
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
BMC Cancer
; 15: 496, 2015 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26141683
10.
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Qual Life Res
; 24(1): 5-18, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24277234
11.
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
Health Qual Life Outcomes
; 12: 69, 2014 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24886671
12.
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
Eur J Cancer
; 199: 113537, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38241818
13.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
JAMA Oncol
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573643
14.
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Eur J Cancer
; 188: 90-97, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229836
15.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Nat Med
; 29(8): 2087-2098, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563240
16.
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Eur J Cancer
; 178: 162-170, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36446161
17.
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.
Cancers (Basel)
; 15(16)2023 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627145
18.
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
Eur J Cancer
; 168: 99-107, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489233
19.
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.
Eur J Cancer
; 174: 142-152, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994794
20.
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
Eur J Cancer
; 163: 1-15, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35033994